GURU.Markets stock price, segment price, and overall market index valuation
The company's share price OCGN
Ocugen is a biotech company whose shares soared on hopes for a COVID-19 vaccine, which it was trying to bring to the US market. Its price chart is a classic example of a speculative biotech bubble, followed by a crash when those hopes failed to materialize.
Share prices of companies in the market segment - Dna
Ocugen is a biopharmaceutical company developing gene therapies for blindness and vaccines, including COVAXIN for COVID-19. We classify it in the DNA Technologies sector. The chart below shows how investors view the prospects of this innovative field.
Broad Market Index - GURU.Markets
Ocugen is a biotech company specializing in the development of gene and cell therapies for eye diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Ocugen shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
OCGN - Daily change in the company's share price OCGN
The daily price change of Ocugen, a biotech company, reflects the sector's extreme volatility. Change_co is an instant reaction to news about clinical trials and partnerships. This metric is the basis for analyzing high-risk assets in the biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Ocugen, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with OCGN, which focuses on eye disease treatments and vaccines, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Ocugen is a biopharmaceutical company developing gene therapies and vaccines. The vaccine sector is extremely volatile, and Ocugen's story is a prime example. The chart below reflects average fluctuations in the industry, providing context for evaluating the company's stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization OCGN
Ocugen, Inc.'s year-to-date performance is the story of a biotech company searching for its breakthrough product. Its 12-month market cap is highly volatile and depends on news in its core businesses: efforts to bring the Covaxin vaccine to the US market and the development of gene therapy for eye diseases.
Annual dynamics of market capitalization of the market segment - Dna
Ocugen, Inc. is a biotech company developing gene therapies for eye diseases and vaccines. Its stock price is highly volatile and dependent on clinical trial results and partnerships, typical of this speculative sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ocugen is a highly speculative biotech company. Its stock price has nothing to do with fundamentals or the economy, but is driven by rumors, hype, and hopes for drug approval. The chart is an example of how stocks can be completely disconnected from reality.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization OCGN
Ocugen, a biopharmaceutical company, has a speculative market cap. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its eye disease treatments and vaccines, the success of which determines its entire future value.
Monthly dynamics of market capitalization of the market segment - Dna
Ocugen is a biotech company developing gene and cell therapies to treat blindness. The company also gained notoriety for its attempt to bring an Indian COVID-19 vaccine to the US market. The chart below shows the dynamics of the volatile biotech sector, where news can cause sharp price movements.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ocugen is a biotech company focused on gene therapy for blindness and vaccine development. Its shares are extremely volatile, driven by news of clinical trials and partnerships. The company's performance is completely unrelated to overall market trends, making it a classic example of a biotech bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization OCGN
Ocugen is a biotech company working on gene therapy for blindness and vaccines. Its weekly stock price is extremely volatile, driven by news about clinical trials and FDA decisions. The chart reflects the high stakes and speculative interest in its developments.
Weekly dynamics of market capitalization of the market segment - Dna
Ocugen, like the entire speculative biotech sector, is extremely volatile. Weekly stock fluctuations in this segment often reflect broader scientific breakthroughs or setbacks that impact investor interest in the entire sector. The chart illustrates this sectoral relationship.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Ocugen is a biotech company whose popularity soared during the pandemic. Its shares are extremely volatile, driven by development news. The chart clearly shows how disconnected its weekly performance is from the broader market, living in a world of investor hopes and speculation.
Market capitalization of the company, segment and market as a whole
OCGN - Market capitalization of the company OCGN
The chart of Ocugen, Inc. reflects the extreme volatility of biotech speculation. Its market cap soared on hopes of a COVID-19 vaccine, then corrected. The chart shows how market valuations can deviate from fundamentals in anticipation of a breakout.
OCGN - Share of the company's market capitalization OCGN within the market segment - Dna
Ocugen, Inc. is a biotech company whose market share is based on its pipeline of gene therapy developments for eye diseases and its COVID-19 vaccine partnership. Its market capitalization reflects its diverse, yet risky, projects.
Market capitalization of the market segment - Dna
Ocugen is working on gene therapy and vaccines. How big is this arena? The chart below shows the pulse of the DNA technology sector. Its extreme volatility reflects both the enormous potential for treating blindness and the high risks associated with developing new vaccines.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Ocugen chart shows how the market values a biotech company with a broad but risky portfolio. Its market cap is a speculative bet on the success of its developments in eye gene therapy and vaccines. It's a volatile chart, reflecting the pursuit of the next big breakthrough in medicine.
Book value capitalization of the company, segment and market as a whole
OCGN - Book value capitalization of the company OCGN
For Ocugen, a biotech company working on ocular gene therapy and vaccines, book value is its tangible assets: laboratories, manufacturing contracts, and financial reserves for R&D. The chart below shows how the company built its physical and financial foundation for innovation.
OCGN - Share of the company's book capitalization OCGN within the market segment - Dna
Ocugen, Inc. is a biopharmaceutical company whose tangible assets include laboratories and partner manufacturing facilities for developing vaccines and gene therapies for the eye. The chart shows the share of this specialized R&D and manufacturing infrastructure the company aims to capture in its therapeutic areas.
Market segment balance sheet capitalization - Dna
Ocugen is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Ocugen focuses on drug development, and its capital comes from its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Ocugen's core assets include laboratories and partner manufacturing facilities for developing gene therapies for blindness and vaccines. The chart below shows how the company built its scientific and physical capital to advance its innovative projects.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - OCGN
Ocugen is a biotech company. Its market valuation is pure speculation on the success of its developments. The chart is a visualization of extreme volatility based on news about clinical trials and partnerships.
Market to book capitalization ratio in a market segment - Dna
Ocugen is a biotech company working on gene therapy for blindness and vaccine development. Its valuation is highly volatile and depends on news about clinical trials. The chart shows how its market capitalization, driven by hopes, relates to its assets.
Market to book capitalization ratio for the market as a whole
Ocugen is a biopharmaceutical company working on gene therapy for blindness and vaccines. Its valuation is highly volatile and dependent on news about clinical trials. Compared to the average, its market cap is unrelated to its assets, but rather represents investors' pure bet that one of its projects will be successful.
Debts of the company, segment and market as a whole
OCGN - Company debts OCGN
Ocugen is a biotech company that gained attention for its attempt to bring an Indian-made COVID-19 vaccine to the US market. This chart shows how the company is funding its diverse, yet risky, gene therapy and vaccine projects. Funding is provided exclusively through equity issuance, as the company has no stable revenue stream.
Market segment debts - Dna
Ocugen, a biotech company that gained attention for its attempt to bring an Indian-made COVID-19 vaccine to the US market, is now focusing on gene therapy for eye diseases. This chart shows how its debt policy reflects this shift in strategy and its need for capital to fund its new, long-term research programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio OCGN
Ocugen is a biotech company working on vaccines and gene therapy to treat blindness. Its future depends on the success of clinical trials. This chart shows how much the company finances its expensive research with debt. It reflects the level of financial risk investors are taking in anticipation of breakthrough results.
Market segment debt to market segment book capitalization - Dna
Ocugen is a biotech company developing gene therapies for blindness and vaccines. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its diverse and risky clinical programs, each of which requires significant capital.
Debt to book value of all companies in the market
Ocugen is a biotech company working on gene therapies to treat blindness and vaccine development. Its operations require massive investments in clinical research. This chart, showing the overall market appetite for debt risk, is an indicator of how easily companies of this type can attract the necessary financing.
P/E of the company, segment and market as a whole
P/E - OCGN
Ocugen is a biotech company that initially focused on treating blindness but gained widespread recognition for its attempt to bring the Indian COVID-19 vaccine Covaxin to the US market. This chart reflects the speculative nature of its operations. Its performance is heavily dependent on regulatory approvals rather than fundamentals.
P/E of the market segment - Dna
Ocugen is a biotech company developing gene and cell therapies for rare eye diseases. The company is also known for its partnership to develop and commercialize the COVID-19 vaccine Covaxin. This chart shows the overall valuation of the DNA technologies sector, reflecting how investors value companies with a diversified pipeline.
P/E of the market as a whole
Ocugen is a biotech company that gained notoriety for its attempt to bring an Indian COVID-19 vaccine to the US market. It is currently focused on gene therapy for the eye. Its valuation reflects investor expectations for its research programs. It is not tied to the overall economic trends shown in this chart, but rather depends on research data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company OCGN
Ocugen, Inc. is a biotech company developing gene therapies for eye diseases and vaccines. It gained notoriety for its partnership on the COVID-19 vaccine Covaxin. This chart reflects speculative expectations for its diverse but risky portfolio. Its valuation is contingent on the success of clinical trials.
%20P%2FE%20OCGN&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-OCGN&v=1772573726393 "Chart of the company's future (projected) P/E OCGN")
Future (projected) P/E of the market segment - Dna
Ocugen is a biotech company focused on developing gene therapies for blindness and vaccines. This chart reflects speculative expectations for its research programs. Comparing its future revenue projections with the sector reveals how much investors believe in the success of its clinical trials and the commercial potential of its developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772573726575 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Ocugen is a biotech company working on gene therapies to treat blindness and vaccine development. Its shares are highly volatile and react to news about clinical trials. This chart of overall risk appetite provides the backdrop, but for Ocugen, a single successful or unsuccessful trial result can be far more important than overall market trends.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772573726675 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit OCGN
Ocugen, Inc. is a biotechnology company developing gene therapies for ocular diseases and vaccines. The company is in the clinical stage of development. This graph reflects research and development expenses, and future revenue is entirely dependent on the successful registration and commercialization of its product candidates.
Profit of companies in the market segment - Dna
Ocugen is a biotech company developing gene and cell therapies for blindness, as well as vaccines. The company is working on breakthrough but risky projects. The profitability curve in its sector reflects the binary nature of biotech: the success of one drug can lead to explosive growth, while a failure in trials can lead to a sharp decline in investor interest in the entire technology.
Overall market profit
Ocugen is a biotechnology company developing gene therapies for rare eye diseases, as well as vaccines. The company operates at the forefront of science. Its success depends on clinical trial results and regulatory approval. Potential breakthroughs in this field could have a profound impact on patients' lives and the entire healthcare industry.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company OCGN
Ocugen is a biotech company working on gene therapy for blindness and vaccine development. This chart reflects speculative expectations for its diverse but early pipeline. Future profits depend on successful clinical trials in either area.
%20profit%20of%20the%20company%20OCGN&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-OCGN&v=1772573726983 "Graph of future (projected) profit of the company OCGN")
Future (predicted) profit of companies in the market segment - Dna
Ocugen, Inc. is a biotech company working on gene therapy for eye diseases and vaccine development. This chart shows projected revenue growth for the biotech sector. It helps assess how the company's diversified, yet risky, development pipeline aligns with industry expectations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772573727098 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Ocugen, a biopharmaceutical company, is projecting profits based on the success of its gene therapy developments for eye diseases. This chart reflects investor expectations for clinical trial results. Previous projects related to a COVID-19 vaccine also contributed to volatility, but the focus has shifted to the core platform.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772573727135 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - OCGN
Ocugen, a biopharmaceutical company best known for its efforts to bring a COVID-19 vaccine to market, is now focusing on gene therapy. This chart shows a valuation based on the future potential of its developments, not current revenue, which is negligible. This is a bet on success in clinical trials.
P/S market segment - Dna
Ocugen is a biotech company developing gene therapies for blindness and vaccines. Its valuation is based on the future revenue potential of these breakthrough products. This chart shows the average valuation in the sector, reflecting investor expectations for the commercial success of Ocugen's developments, particularly its flagship ophthalmology programs.
P/S of the market as a whole
Ocugen is a biotech company developing gene therapies for blindness, as well as vaccines. Its valuation is heavily dependent on news about clinical trials and regulatory approvals. This chart, showing the average revenue estimate for Ocugen, highlights that in biotech, valuations often reflect expectations rather than actual cash flows.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company OCGN
Ocugen is a biotech company working on gene therapy for eye diseases and vaccine development. The company has no stable revenue. This chart reflects investor expectations for its developments. It shows the market's assessment of the likelihood of success in its clinical trials, particularly for rare genetic diseases.
%20P%2FS%20OCGN&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-OCGN&v=1772573727426 "The graph of the company's future (projected) P/S OCGN")
Future (projected) P/S of the market segment - Dna
Ocugen is a biopharmaceutical company developing gene therapies for eye diseases and vaccines. This chart compares market expectations for its future revenue with other companies in the DNA technology sector. The valuation reflects speculative investor expectations for its clinical programs, including the COVID-19 vaccine Covaxin.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772573727566 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Ocugen is a biotech company working on gene therapy for eye diseases and is also known for its attempt to bring the Covaxin vaccine to the US market. Its future depends on success in clinical development. The company's potential to create breakthrough treatments is part of the overall optimism surrounding medical innovation.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772573727622 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales OCGN
Ocugen is a biotech company developing gene therapies for blindness and vaccines. While in the development stage, it may not have stable sales revenue. This chart will begin to show revenue after the commercialization of its products or receipt of advance payments under partnership agreements.
Sales of companies in the market segment - Dna
Ocugen, Inc. is a biotech company developing gene and cell therapies to treat blindness. The company also gained notoriety for its efforts to bring an Indian COVID-19 vaccine to the US market. This chart shows overall pharmaceutical sales, reflecting the high potential and risks of early-stage biotech development.
Overall market sales
Ocugen is a biotech company developing gene and cell therapies for blindness, as well as vaccines. This overall economic activity chart for Ocugen is important through the lens of funding. For companies in the development stage without stable revenue, access to capital, which is facilitated by a healthy economy, is vital.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company OCGN
Ocugen is a biotechnology company developing gene therapies for eye diseases, as well as vaccines. Future revenue depends on the success of its clinical programs and regulatory approvals. This chart reflects analysts' speculative expectations regarding the scientific potential and commercial prospects of the company's developments.
%20sales%20of%20the%20company%20OCGN&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-OCGN&v=1772573727941 "Schedule of future (projected) sales of the company OCGN")
Future (projected) sales of companies in the market segment - Dna
Ocugen, Inc. is a biotechnology company developing gene and cell therapies to treat blindness and vaccines. This chart shows projected revenue for the entire biotech sector. While it reflects general sentiment, Ocugen's success depends entirely on the results of its clinical programs and regulatory approvals.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772573728062 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Ocugen is a biopharmaceutical company developing gene therapies for blindness and vaccines. The company is in the development stage, and its value depends on the results of clinical trials. This chart, reflecting economic sentiment, influences investors' risk appetite and their willingness to fund companies that are not yet profitable but have high future potential.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772573728077 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality OCGN
Ocugen is a biotech company working on gene therapy for blindness and vaccine development. The chart for such a company reflects its financial health as it moves toward commercialization. It shows how Ocugen manages its clinical trial costs in its quest to bring breakthrough medical solutions to market.
Market segment marginality - Dna
Ocugen is a biopharmaceutical company working on gene therapies for eye diseases and vaccine development. This chart reflects its operational structure at the clinical development stage. It highlights the high R&D costs required to develop breakthrough treatments and allows for comparison with other biotech companies at a similar stage.
Market marginality as a whole
Ocugen is a biopharmaceutical company focused on developing gene therapies for blindness and vaccines. Its future profitability depends on the success of its clinical programs and partnerships. This total market profitability chart serves as a contrast to biotech, where the potential for breakthrough treatments can drive tremendous growth despite overall economic conditions.
Employees in the company, segment and market as a whole
Number of employees in the company OCGN
Ocugen is a biotech company focused on developing gene therapies for blindness and vaccines. This chart shows a small team. The headcount dynamics reflect the stages of clinical development. The sharp but temporary increase could be related to the company's efforts to bring the Covaxin vaccine to market during the pandemic.
Share of the company's employees OCGN within the market segment - Dna
This indicator demonstrates Ocugen, Inc.'s ambitions in biotechnology. The company's share of this sector is focused on developing gene therapies for rare eye diseases. Furthermore, the company is known for its efforts to bring the Indian COVID-19 vaccine Covaxin to the North American market, reflecting its diversified strategy.
Number of employees in the market segment - Dna
Ocugen, Inc. is a biopharmaceutical company developing gene and cell therapies for blindness, as well as vaccines. Working at the cutting edge of science requires attracting the best specialists. This graph illustrates how biotech breakthroughs, particularly in ophthalmology, are creating a demand for unique scientific talent capable of restoring sight.
Number of employees in the market as a whole
Ocugen, Inc. is a biotech company developing gene therapies to treat blindness. Its future depends on the success of its research programs, not on the economic cycles shown in this chart. The company operates at the forefront of medicine, where one successful drug can change everything.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company OCGN (OCGN)
Ocugen is a biotech company developing gene therapy for blindness and vaccines. This chart reflects the speculative nature of biotech. The very high market capitalization per employee suggests that investors are assessing not current performance, but the potential success of one of its drugs, which could generate huge profits in the future.
%20of%20the%20company%20OCGN%20(OCGN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-OCGN-OCGN&v=1772573728694 "Chart of market capitalization per employee (in thousands of dollars) of the company OCGN (OCGN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Ocugen is a biotech company working on gene therapy for blindness and vaccine development. Its per-employee value reflects the market valuation of its scientific platform. The chart shows the premium investors place on a potential breakthrough in treating rare diseases by a small research team.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772573728724 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Ocugen, Inc. is a biotech company focused on gene therapy for blindness and vaccine development. This chart shows a high valuation per employee, typical for R&D companies without stable revenue. The company's value reflects investors' bets on the success of its clinical trials and future products.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772573728746 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company OCGN (OCGN)
Ocugen is a biotech company that rose to prominence during the pandemic by unsuccessfully attempting to bring the Indian vaccine Covaxin to the US market. They are now focusing on gene therapy for the eyes. This graph (negative) shows their cash burn rate. They are a venture-backed company spending money on R&D in the hopes of future success.
%20Chart%20OCGN%20(OCGN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-OCGN-OCGN&v=1772573728795 "Company Profit Per Employee (in thousands of dollars) Chart OCGN (OCGN)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Ocugen is a biotech company developing gene therapies for blindness and (previously) the Covaxin vaccine. In biotech, this chart shows the loss per employee during R&D. It serves as a benchmark for assessing how intensively a company is investing in its research programs, where each scientist is working on a potentially breakthrough but currently unprofitable product, compared to its competitors.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772573728985 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Ocugen (OCGN) is a biotech company that gained notoriety for its efforts to bring the Indian vaccine Covaxin to the US market. They are also developing gene therapy for the eye. This (likely negative) graph reflects a "lottery ticket" business model. They are spending money on a small staff while trying to secure regulatory approval. Success would result in explosive profit per employee, but for now, it's just a cost.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772573729053 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee OCGN (OCGN)
Ocugen is a biotech company developing gene therapies for blindness and vaccines. This chart reflects the company's activity in the clinical development stage. Revenue per employee is minimal and depends on partnerships rather than sales.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-OCGN-OCGN&v=1772573729087 "Sales chart per company employee OCGN (OCGN)")
Sales per employee in the market segment - Dna
Ocugen is a biotech company developing gene therapy for blindness and (previously) the Covaxin vaccine. This chart shows the average revenue per employee in the segment. For a company with products in development, it serves as a benchmark for performance in a sector where revenue often depends on partnerships.
Sales per employee for the market as a whole
Ocugen is a biotech company. They became known for their attempt to bring the Indian vaccine Covaxin to the US market, but their primary focus is developing gene therapy for blindness. They have no commercial revenue. This figure would be zero, as their team is focused on R&D and clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company OCGN (OCGN)
Ocugen is a biotech company that gained notoriety during the pandemic for its efforts to bring the Covaxin vaccine to the US market. This chart shows the bets of those who don't believe in its success. Bears point to the lack of approved products, high capital burn rate, and history of failures, making its R&D projects highly speculative.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-OCGN-OCGN&v=1772573729188 "Short Shares Chart for the Company OCGN (OCGN)")
Shares shorted by market segment - Dna
Ocugen is a biotech company best known for its efforts to bring the Indian vaccine Covaxin to the US market. It is also developing gene therapy for the eye. This chart reflects the overall sentiment in the sector. It reflects investor skepticism toward biotech companies that rely on partnerships rather than strong in-house R&D platforms.
Shares shorted by the overall market
Ocugen (OCGN) is a speculative biotech company. Its fame stems from the failed attempt to develop the Covaxin vaccine. When this market fear curve rises, investors completely lose their "risk appetite." They sell off "lottery ticket stocks" without revenue, like OCGN, en masse in favor of real and profitable businesses.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator OCGN (OCGN)
Ocugen is a speculative biotech whose shares soared on hopes for the Covaxin COVID vaccine and are now focused on gene therapy for blindness. This chart measures the extremes of investor emotion. It shows when the hype around R&D news (overbought zone) or despair over FDA delays (oversold zone) peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-OCGN-OCGN&v=1772573729334 "RSI 14 indicator chart for the company's stock OCGN (OCGN)")
RSI 14 Market Segment - Dna
Ocugen is a biopharmaceutical company focused on gene therapy for blindness (Ocu-ology) and vaccine development (including Covaxin). Their business is high-risk, high-reward R&D. This chart shows the overall sentiment in the speculative biotech sector. It helps assess whether the entire segment is overheated by general hype, or whether Ocugen's move is driven by news about specific trials.
RSI 14 for the overall market
For Ocugen, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OCGN (OCGN)
Ocugen (OCGN) is a biotech company best known for its unsuccessful partnership on the Covaxin vaccine (developed in India) for the US market. The company is now focusing on gene therapy for the eye. This chart shows the average Wall Street forecast, reflecting analysts' speculative valuations of its ophthalmology developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OCGN-OCGN&v=1772573729535 "A chart showing analyst consensus forecasts for the expected stock price. OCGN (OCGN)")
The difference between the consensus estimate and the actual stock price OCGN (OCGN)
Ocugen (OCGN) is a biotech that rose to prominence by unsuccessfully attempting to bring the Indian COVID vaccine (Covaxin) to the US market and is now focusing on gene therapy for the eye. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting how confident analysts are in their new ophthalmology pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OCGN-OCGN&v=1772573729580 "A chart showing the difference between the consensus forecast and the actual stock price. OCGN (OCGN)")
Analyst consensus forecast for stock prices by market segment - Dna
Ocugen is a biotech company that rose to prominence during the pandemic by attempting to bring the Indian vaccine Covaxin to the US market. The company is currently focused on gene therapy for blindness. This chart shows general expectations for the DNA sector. It reflects whether experts believe the company's ophthalmology R&D platform will be successful.
Analysts' consensus forecast for the overall market share price
Ocugen is a biotech company that rose to prominence during the pandemic thanks to its efforts to bring the Indian vaccine Covaxin to the US market. It is also developing gene therapy for the eye. This chart shows overall risk appetite. For Ocugen, a high-risk company with a speculative reputation, overall market optimism is critical to attracting investor attention.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index OCGN
Ocugen (OCGN) is a biotech that rose to prominence during COVID by unsuccessfully attempting to bring an Indian vaccine (Covaxin) to the US market. Their legacy is gene therapy for the eye. This chart represents their R&D bet. Its valuation (after the COVID hype collapsed) reflects the market's faith in their (very early) scientific platform for treating blindness.
AKIMA Market Segment Index - Dna
Ocugen (OCGN) is a speculative biotech; the company (without any products) attempted to bring an Indian vaccine (Covaxin) to the US market and is developing gene therapies for eye diseases. This composite metric measures R&D. The chart shows the segment average. This benchmark: how does this high-risk R&D model (OCGN) compare to the average pharma company?
The AKIM Index for the overall market
Ocugen is a biopharmaceutical company developing gene therapy for blindness and vaccines. It's known for its volatility. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative story, driven by news and hopes, compares to overall economic trends and retail investor appetite.
